



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

Program on Thursday, 16 February 2017

08:00

State of the Art, Room Boston 1+2

Von Willebrand Factor

Chairs:

F. Langer (Hamburg, Germany)

B. Zieger (Freiburg, Germany)

08:00

Von Willebrand factor processing

M. A. Brehm (Hamburg, Germany)

08:25

Acquired Von Willebrand syndrome in patients with aortic valve disease

S. Susen (Lille Cedex, France)

08:50

Effect of DDAVP on hemostasis - more than just VWF release

L. Alberio (Lausanne, Switzerland)

08:00

State of the Art, Room Delhi

Platelets

Chairs:

K. Jurk (Mainz, Germany)

J. Koscielny (Berlin, Germany)

08:00

Indications and triggers for platelet transfusions

B. Mansouri Taleghani (Bern, Switzerland)

08:25

In vitro platelet production

D. Baruch (Paris, France)

08:50

Platelet proteomics

R. Zahedi (Dortmund, Germany)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

08:00

Special Symposium, Room Montreal Factor XIII Structure and Functions

Chairs:

H.-P. Kohler (Bern, Switzerland)

L. Muszbek (Debrecen, Hungary)

08:00

Novel biochemical and structural aspects of FXIII L. Muszbek (Debrecen, Hungary)

08:25

FXIII and fibrin structure R. Ariëns (Leeds, United Kingdom)

08:50

FXIII-A in energy metabolism M. Kaartinen (Montreal, Canada)

08:00

Oral Communications, Room Shanghai 1+2 Laboratory

Chairs:

L. Graf (St. Gallen, Switzerland)

M. Spannagl (Munich, Germany)

08:00

The implementation of a high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders: lessons learned from an international study.

T. Bakchoul (Tübingen, Germany)

H. Schulze (Tübingen, Germany)

E. Simeoni (Tübingen, Germany)

W. Ouwehand (Tübingen, Germany)

E. Turro (Tübingen, Germany)

08:12

Diagnosing heparin-induced thrombocytopenia (HIT) in 30 minutes : A prospective evaluation of a rapid diagnostic work-up.

M. Marchetti (Lausanne, Switzerland)

S. Barelli (Lausanne, Switzerland)

F. Monnin (Lausanne, Switzerland)

N. Nicolas (Lausanne, Switzerland)

E. Matthey (Lausanne, Switzerland)

C. Gerschheimer (Lausanne, Switzerland)

L. Alberio (Lausanne, Switzerland)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

08:24

Multianalyte determination of NOAC using LC-MS/MS and comparison with functional coagulation assays

L. Slavik (Olomouc, Czech Republic)
J. Lukes (Olomouc, Czech Republic)
M. Zhanelova (Olomouc, Czech Republic)
M. Nemcova (Olomouc, Czech Republic)
J. Ulehlova (Olomouc, Czech Republic)
J. Prochazkova (Olomouc, Czech Republic)
A. Hlusi (Olomouc, Czech Republic)
M. Palova (Olomouc, Czech Republic)
J. Vaclavik (Olomouc, Czech Republic)

08:36

Fibrin clot formation properties in patients on treatment with oral anticoagulants correlate with drug concentration and intensity of anticoagulation

O. Königsbrügge (Vienna, Austria)
G. Weigel (Innsbruck, Austria)
I. Pabinger (Vienna, Austria)
C. Ay (Vienna, Austria)

08:48

Spatial fibrin clot formation is less affected by clotting factor deficiency than thrombin generation

E. Zöhrer
A. Schlagenhaut
S. Pohl
B. Leschnik
H. Haidl
S. Gallistl

09:00

Catching microparticles - a methodical comparison

C. Plattfaut (Lübeck, Germany)
F. Gieseler (Lübeck, Germany)
A. Freund (Lübeck, Germany)
G. Riemekasten (Lübeck, Germany)
A. Müller (Lübeck, Germany)

08:00

State of the Art, Room Singapore
VTE Management

Chairs:

R. Bauersachs (Darmstadt, Germany)
S. Konstantinides (Mainz, Germany)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

08:00

Predictive variables of recurrence - how to choose long-term anticoagulation in VTE
P. A. Kyrle (Vienna, Austria)

08:25

Advantages and limitations of patient self-management of oral anticoagulation in VKA
W. A. Wuillemin (Luzern, Switzerland)

08:50

Post-thrombotic syndrome - implications and management
A. ten Cate-Hoek (Maastricht, The Netherlands)

08:00

State of the Art, Room Sydney
Pediatric - Hemostasis

Chairs:

K. Kurnik (Munich, Germany)

N. von der Weid (Basel, Switzerland)

08:00

Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate
E. Berntorp (Malmö, Sweden)

08:25

Gynecological aspects of adolescents with rare bleeding disorders
R. Kulkarni (East Lansing, United States)

08:50

Care, needs and perceptions of adolescents and young adults growing up with hemophilia A or B in Germany

D. Richter

C. Heller

M. Heuer

S. Schultze-Strasser

D. Schwabe

C. Königs

09:02

An alternative immune tolerance induction therapy for patients with inhibitors in hemophilia A

W.-A. Hassenpflug (Hamburg, Germany)

J. Schrum (Hamburg, Germany)

R. Dittmer (Hamburg, Germany)

R. Schneppenheim (Hamburg, Germany)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

09:30

Plenary Session I, Room San Francisco

Chairs:

M. A. Brehm (Hamburg, Germany)

E. R. Weibel (Bern, Switzerland)

09:30

Life cycle of Weibel Palade bodies

H. J. Eikenboom (Leiden, The Netherlands)

10:00

Regulation of angiogenesis by Von Willebrand factor

A. Randi (London, United Kingdom)

10:30

Bayer Thrombosis Award, Room San Francisco

Announcement and Presentation of Awardee

Bayer Science and Education Foundation

10:45

Special Symposium, Room Montreal

Clinical Aspects of Factor XIII

Chairs:

A. Ichinose (Yamagata, Japan)

V. Schröder (Bern, Switzerland)

10:45

Functional and clinical aspects of FXIII

H.-P. Kohler (Bern, Switzerland)

11:10

The first case of congenital FXIII deficiency - A Swiss story

V. Schröder (Bern, Switzerland)

11:35

Acquired FXIII deficiency

A. Ichinose (Yamagata, Japan)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

12:00

Coagulation factor XIII: its possible role in corneal wound healing

Z. Z. Orosz (Debrecen, Hungary / Szeged, Hungary)

A. Szöör (Debrecen, Hungary)

Z. Veréb (Szeged, Hungary)

Z. Hassan (Debrecen, Hungary)

E. Katona (Debrecen, Hungary)

G. Vereb (Debrecen, Hungary)

A. Facskó (Szeged, Hungary)

L. Muszbek (Debrecen, Hungary)

11:00

Highlight Session I, Room Boston 1+2

Miscellaneous

Chairs:

B. Kehrel (Muenster, Germany)

M. Skowronska (Bern, Switzerland)

11:00

New treatment options for thrombotic thrombocytopenic purpura (TTP)

P. Knöbl (Vienna, Austria)

11:20

Clinical Pearl

B. Kemkes-Matthes (Giessen, Germany)

11:35

Warfarin inhibits VKORC1 by competitive slow tight binding

K. J. Czogalla (Bonn, Germany)

A. Biswas (Bonn, Germany)

K. Höning (Bonn, Germany)

V. Hornung (Bonn, Germany / Munich, Germany)

K. Liphardt (Bonn, Germany)

M. Watzka (Bonn, Germany)

J. Oldenburg (Bonn, Germany)

11:47

Cardiac Protease-Activated Receptor 2 expression is involved in cardiac fibrosis, diastolic dysfunction and immunological response in the aged heart

J. Friebe (Berlin, Germany)

M. Witkowski (Berlin, Germany)

A. Weithäuser (Berlin, Germany)

K. Savvatis (London, United Kingdom)

D. Steffens (Berlin, Germany)

M. Kasner (Berlin, Germany)

T. Tabaraie (Berlin, Germany)

M. Wegner (Berlin, Germany)

U. Landmesser (Berlin, Germany)

U. Rauch-Kröhnert (Berlin, Germany)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

11:00

Best Poster, Room Shanghai 3+4

Basic Science

Chairs:

M. Schaller Tschan (Bern, Switzerland)

W. A. Wuillemin (Luzern, Switzerland)

11:00

Differential effects of novel anticoagulants: FXa versus FIIa inhibition on coagulation and inflammation

S. Nazir (Magdeburg, Germany)

K. Shahzad (Magdeburg, Germany)

I. Gadi (Magdeburg, Germany)

M. Al-Dabet (Magdeburg, Germany)

S. Kohli (Magdeburg, Germany)

S. Ranjan (Magdeburg, Germany)

F. Bock (Magdeburg, Germany / Nashville, United States)

B. Isermann (Magdeburg, Germany)

11:06

Annexin A7 (ANX7) regulates collagen-dependent platelet activation and Ca²⁺ signaling

S. Geue (Tübingen, Germany)

B. Walker-Allgaier (Tübingen, Germany)

D. Eißler (Tübingen, Germany)

P. Münzer (Tübingen, Germany)

F. Lang (Tübingen, Germany)

M. Gawaz (Tübingen, Germany)

O. Borst (Tübingen, Germany)

11:12

P2Y6 depletion enhances metabolic activity and ameliorates outcome of high fat diet induced obesity in mice

J. Merz (Freiburg, Deutschland)

P. Stachon (Freiburg, Deutschland)

P. Albrecht (Freiburg, Deutschland)

F. Ünal (Freiburg, Deutschland)

S. von Garlen (Freiburg, Deutschland)

A. Heidenreich (Freiburg, Deutschland)

N. Hoppe (Freiburg, Deutschland)

B. Duffner (Freiburg, Deutschland)

C. Bode (Freiburg, Deutschland)

A. Zirlik (Freiburg, Deutschland)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

11:18

[Introduction of a guideline for the treatment of synovitis in patients with hemophilia](#)

[B. Habermann](#) (Mainz, Germany)

A. Seuser (Bonn, Germany)

T. Hilberg (Wuppertal, Germany)

11:24

[The coagulation Factor XIII \(FXIII\) A subunit activation peptide directs the evolution of FXIIIA as a proteolytically activated dimeric molecule](#)

[A. Biswas](#) (Bonn, Germany)

S. Singh (Bonn, Germany)

V. Ivaskevicius (Bonn, Germany)

J. Oldenburg (Bonn, Germany)

11:30

[CLIC1 supports mechanisms related to thrombosis and vascular repair](#)

[L. M. Knowles](#) (Homburg, Germany)

P. Niewald (Homburg, Germany)

E. Ampofo (Homburg, Germany)

A. Drawz (Homburg, Germany)

I. Müller (Homburg, Germany)

H. Eichler (Homburg, Germany)

J. Pilch (Homburg, Germany)

11:36

[Collagen V alpha 2 as a direct target of miR-143 in arteriogenesis](#)

[T. Hammerschick](#) (Giessen, Germany)

K. Troidl (Bad Nauheim, Germany)

K. T. Preissner (Giessen, Germany)

S. Fischer (Giessen, Germany)

11:42

[Phosphorylation of the protein phosphatase 2A inhibitor alpha-endosulfine \(ENSA\) at two distinct sites, serine 67 and serine 109, in human platelets](#)

[E. Walter](#) (Mainz, Germany)

O. Pagel (Dortmund, Germany)

R. Zahedi (Dortmund, Germany)

A. Smolenski (Dublin, Ireland)

S. Gambaryan (Mainz, Germany / St. Petersburg, Russia)

U. Walter (Mainz, Germany)

K. Jurk (Mainz, Germany)

11:48

[Fucoidans inhibit cellular responses to the chemokine IL-8 and the anaphylatoxin C5a better than heparin](#)

[S. Alban](#) (Kiel, Germany)

K. Ehrig (Kiel, Germany)

I. Liewert (Kiel, Germany)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

11:54

FSAP and altered fibrin clot structure: Is there a link to FXIII?

M. Etscheid (Langen, Germany)

N. Beer (Langen, Germany)

R. Seitz (Langen, Germany)

J. Dodt (Langen, Germany)

11:00

Highlight Session II, Room Singapore

Hemostasis

Chairs:

W. Miesbach (Frankfurt am Main, Germany)

D. Tsakiris (Basel, Switzerland)

11:00

A new era of treatment for patients with hemophilia A with and without inhibitors?

R. Klamroth (Berlin, Germany)

11:15

Clinical Pearl

J.-D. Studt (Zurich, Switzerland)

11:30

IPS derived endothelial cells from Hemophilia A patients with nonsense mutations contain endogenous FVIII and the high risk inhibitor mutation R1941X shows abnormal intracellular trafficking

H. Singer (Bonn, Germany)

N. Nuesgen (Bonn, Germany)

J. Oldenburg (Bonn, Germany)

O. El-Maarri (Bonn, Germany)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

11:47

Targeting anticoagulant protein S to achieve hemostasis in hemophilia

S. Calzavarini (Bern, Switzerland)
L. Bologna (Bern, Switzerland)
R. Prince (Bern, Switzerland)
M. Manetti (Florence, Italy)
D. Melchiorre (Florence, Italy)
I. Rosa (Florence, Italy)
N. Dewarrat (Bern, Switzerland)
P. Amini (Bern, Switzerland)
J.A. Fernandez (La Jolla, USA)
C. Quarroz (Bern, Switzerland)
Y. Matsumura (Chiba, Japan)
J.A. Kremer Hovinga (Bern, Switzerland)
J.H. Griffin (La Jolla, USA)
H-U. Simon (Bern, Switzerland)
L. Ibba Maneschi (Florence, Italy)
F. Saller (Paris, France)
A. Angelillo-Scherrer (Bern, Switzerland)

11:00

Highlight Session III, Room Sydney

Thrombosis

Chairs:

L. Asmis (Zurich, Switzerland)
I. Pabinger-Fasching (Vienna, Austria)

11:00

Highlight Thrombosis

R. E. Scharf (Duesseldorf, Germany)

11:20

Clinical Pearl

C. Ay (Vienna, Austria)

11:35

Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a large multicenter cohort study

F. Dentali (Varese, Italy)
S. Pegoraro (Varese, Italy)
S. Barco (Mainz, Germany)
M. di Minno (Mainz, Germany)
D. Mastroiacovo (Naples, Italy)
F. Pomero (Avezzano, Italy)
C. Lodigiani (Cuneo, Italy)
F. Bagna (Rozzano-Milano, Italy)
W. Ageno (Varese, Italy)
M. di Nisio (Chieti, Italy)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

11:47

Platelet transcriptome analysis of mice with altered thrombin signaling

S. Schubert (Mainz, Germany)

F. Marini (Mainz, Germany)

C. Santos (Mainz, Germany)

H. Binder (Mainz, Germany)

W. Ruf (Mainz, Germany)

12:15

Satellite Symposium CSL Behring GmbH, Room Boston 1+2

Vielfältigkeit von angeborenen Gerinnungsstörungen und Angiopathien - Theorie und Praxis

Chairs:

A. Huth-Kühne (Heidelberg, Germany)

J. A. Kremer Hovinga (Bern, Switzerland)

12:15

Voncento®: Studiendaten und klinische Anwendung

C. Bidlingmaier (Munich, Germany)

12:38

Angeborene Thrombozytopathien und Differentialdiagnose

B. Zieger (Freiburg, Germany)

13:00

Facetten des VWS: Angiodysplasien

W. Eberl (Braunschweig, Germany)

13:22

Faktor IX - ein faszinierendes Molekül

J. A. Kremer Hovinga (Bern, Switzerland)

12:15

Satellite Symposium Bayer, Room Kairo 1+2

Moderne Antikoagulation - Von Pionier- zu Alltagsfragen

Chairs:

B. Kemkes-Matthes (Giessen, Germany)

W. Korte (St. Gallen, Switzerland)

12:15

Begrüssung

W. Korte (St. Gallen, Switzerland)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

12:20

Venöse Thromboembolien - Studienlage und Realität zu Behandlungskonzepten und Therapieansätzen

S. Haas (Munich, Germany)

12:40

NOAKs im Alltag - Gibt es noch Überraschungen?

J. Beyer-Westendorf (Dresden, Germany)

12:55

Diskussion

13:00

Triple-Therapie mit NOAK - Praxis und Studienlage

C. Bode (Freiburg, Germany)

13:20

Praktisches Management in besonderen Situationen - Do's and Dont's

W. A. Wuillemin (Luzern, Switzerland)

13:40

Diskussion

13:40

Zusammenfassung

B. Kemkes-Matthes (Giessen, Germany)

12:15

Satellite Symposium Octapharma GmbH, Room Shanghai 1+2

Challenges and opportunities in hemophilia A and VWD

Chairs:

I. Hegemann (Zurich, Switzerland)

K. Schmitt (Linz, Austria)

12:15

Inhibitor development in haemophilia A - A lifelong challenge

C. Escuriola-Ettingshausen (Mörfelden-Walldorf, Germany)

12:35

How to start treatment in hemophilia A PUPs in the light of the SIPPET study - single center experience

S. Halimeh (Duisburg, Germany)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

13:00

Management of surgeries in VWD - maintaining the balance

L. Graf (St. Gallen, Switzerland)

13:20

Current aspects of prophylaxis in VWD

U. Nowak-Göttl (Kiel, Germany)

12:15

Satellite Symposium Swedish Orphan Biovitrum GmbH, Room Shanghai 3+4

Half-life Extension in Hemophilia - A Practical Guide for Fc Fusion Proteins

Chairs:

D. Tsakiris (Basel, Switzerland)

N. von der Weid (Basel, Switzerland)

12:15

Introduction

D. Tsakiris (Basel, Switzerland)

12:20

Features of recombinant Factor Fc - Immunological potential

F. Nimmerjahn (Erlangen, Germany)

12:40

Elocta & Alprolix -Long term data in adults and adolescents

R. Klamroth (Berlin, Germany)

13:00

Elocta & Alprolix - Long term data in children

C. Wermes (Hanover, Germany)

13:20

How to use Elocta - Real world experience from Bonn

G. Goldmann (Bonn, Germany)

13:40

Conclusion & Discussion

D. Tsakiris (Basel, Switzerland)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

12:15

Satellite Symposium Pfizer Pharma GmbH, Room Sydney

Hämophilie-Therapie in der Zukunft - von guten Prognosen und neuen Behandlungsansätzen

Chairs:

C. Königs (Frankfurt am Main, Germany)

J. Oldenburg (Bonn, Germany)

J. Rischewski (Luzern, Switzerland)

12:15

Neue Konzepte in der Hämophiliebehandlung - Grundlagen der Gentherapie

T. van den Driessche (Brussels, Belgium)

12:45

Fallstricke der Faktorenmessung im Hämostase-Labor

U. Scholz (Leipzig, Germany)

13:15

Haemoassist 2 - eine gute Prognose

A. Tiede (Hanover, Germany)

14:00

Oral Communications, Room Boston 1+2

Innovation and Novelty

Chairs:

Z. Cermakova (Ostrava, Czech Republic)

R. Rieben (Bern, Switzerland)

14:00

Microvascular flow model to study clot formation in real-time

L. Jenny (Bern, Switzerland)

J. Dobó (Budapest, Hungary)

P. Gál (Budapest, Hungary)

W. Lam (Atlanta, United States)

V. Schroeder (Bern, Switzerland)

14:12

rhADAMTS13 treatment improves ventricular remodeling and functionality after cardiac injury in mice

T. Witsch (Freiburg, Germany / Boston, USA)

K. Martinod (Boston, USA)

D. D. Wagner (Boston, USA)



14:24

Activated protein C is a sensitive biomarker to monitor the activity level of the hemostatic system after activation by recombinant activated factor VII

H. Rühl (Bonn, Germany)
C. Berens (Bonn, Germany)
F. I. Winterhagen (Bonn, Germany)
J. Müller (Bonn, Germany)
J. Oldenburg (Bonn, Germany)
B. Pötzsch (Bonn, Germany)

14:36

In vitro evaluation of aptamer-based reversible inhibition of anticoagulant activated protein C as a novel supportive hemostatic approach

N. Shahidi Hamedani (Bonn, Germany)
H. Rühl (Bonn, Germany)
S. Gasper (Bonn, Germany)
J. J. Zimmermann (Bonn, Germany)
T. Heiseler (Dreieich, Germany)
J. Oldenburg (Bonn, Germany)
G. Mayer (Bonn, Germany)
B. Pötzsch (Bonn, Germany)
J. Müller (Bonn, Germany)

14:48

Regulation of complement and contact system activation via C1 inhibitor potentiation and factor XIIa activity modulation by heparins, glycosaminoglycans and other sulfated glycans

S. Alban (Kiel, Germany)
E. Lahrsen (Kiel, Germany)
A.-K. Schoenfeld (Kiel, Germany)

15:00

Interim results from a dose escalating study of AMT-060 (AAV5-hFIX) gene transfer in adult patients with severe haemophilia B

W. Miesbach (Frankfurt, Germany)
M. Tangelder (Amsterdam, The Netherlands)
K. Meijer (Groningen, The Netherlands)
G. Castaman (Florence, Italy)
F. Cattaneo (Parma, Italy)
M. Coppens (Amsterdam, The Netherlands)
P. Kampmann (Copenhagen, Denmark)
R. Klamroth (Berlin, Germany)
R. Schutgens (Utrecht, The Netherlands)
E. Seifried (Frankfurt, Germany)
J. Schwaeble (Frankfurt, Germany)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

14:00

State of the Art, Room Montreal

Women Issues

Chairs:

Y. Fujimura (Nara, Japan)

B. Lämmle (Mainz, Germany)

14:00

Management of pregnancy in carriers of hemophilia and rare bleeding disorders

U. Scholz (Leipzig, Germany)

14:25

Insights into preeclampsia and HELLP

M. Mohaupt (Bern, Switzerland)

14:50

Pregnancy in patients with acquired and hereditary TTP

A. S. von Krogh (Trondheim, Norway)

14:00

Oral Communications, Room Shanghai 1+2

Vascular Wall, Platelets and Acquired Problems

Chairs:

T. Bakchoul (Tuebingen, Germany)

C.-E. Dempfle (Mannheim-Lindenhof, Germany)

14:00

Role of platelet factor 4 (PF4) and anti-PF4/polyanion IgG in human platelet FcγRIIA mediated anti-bacterial activity

R. Palankar (Greifswald, Germany)

T. Kohler (Greifswald, Germany)

N. Medvedev (Greifswald, Germany)

J. Wesche (Greifswald, Germany)

K. Krauel (Greifswald, Germany)

S. Hammerschmidt (Greifswald, Germany)

A. Greinacher (Greifswald, Germany)



14:12

Platelet activation and aggregation provoked by *Staphylococcus aureus* secreted proteins

U. Binsker (Greifswald, Germany)
J. Wesche (Greifswald, Germany)
R. Palankar (Greifswald, Germany)
T. P. Kohler (Greifswald, Germany)
J. Prucha (Greifswald, Germany)
B. Bröker (Greifswald, Germany)
U. Mamat (Borstel, Germany)
J. Pané-Farré (Greifswald, Germany)
F. Schmidt (Greifswald, Germany)
A. Greinacher (Greifswald, Germany)
S. Hammerschmidt (Greifswald, Germany)

14:24

Altered platelet lipidomic profile influences thrombotic disposition: modulation by the CXCL12-CXCR4-CXCR7 Axis

M. Chatterjee (Tübingen, Germany)
D. Rath (Tübingen, Germany)
J. Schlotterbeck (Tübingen, Germany)
J. Rheinlaender (Tübingen, Germany)
B. Walker-Allgaier (Tübingen, Germany)
T. E. Schäffer (Tübingen, Germany)
M. Lämmerhofer (Tübingen, Germany)
M. Gawaz (Tübingen, Germany)

14:36

Metformin alters the epigenetic regulation of tissue factor in diabetes

M. Witkowski (Berlin, Germany)
A. Weithauser (Berlin, Germany)
T. Tabaraie (Berlin, Germany)
D. Steffens (Berlin, Germany)
J. Friebe (Berlin, Germany)
A. Doerner (Berlin, Germany)
M. Kasner (Berlin, Germany)
B. Stratmann (Bad Oeyenhausen, Germany)
D. Tschoepe (Bad Oeyenhausen, Germany)
U. Landmesser (Berlin, Germany)
U. Rauch (Berlin, Germany)

14:48

D-Dimer, but not the Khorana score predicts venous thromboembolism in lung cancer patients

E. Grilz (Vienna, Austria)
O. Königsbrügge (Vienna, Austria)
J. Riedl (Vienna, Austria)
J. Thaler (Vienna, Austria)
R. Pirker (Vienna, Austria)
C. Ay (Vienna, Austria)
I. Pabinger (Vienna, Austria)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

15:00

Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks

B. Giannetti (Leiden, The Netherlands)

V. Grivcheva Panovska (Skopje, Republic of Macedonia)

D. Moldovan (Tirgu Mures, Romania)

A. Reshef (Tel-Hashomer, Israel)

S. Andrejevic (Belgrade, Serbia)

R. Hakl (Brno, Czech Republic)

S. Kivity (Tel Aviv, Israel)

L. Bellizzi (Leiden, The Netherlands)

A. Relan (Leiden, The Netherlands)

B. Giannetti (Leiden, The Netherlands)

M. Cicardi (Milan, Italy)

14:00

State of the Art, Room Singapore

Hemophilia & Inhibitors

Chairs:

G. Auerswald (Bremen, Germany)

C. Königs (Frankfurt am Main, Germany)

14:00

Role and mode of action of T cells in inhibitor formation in hemophilia A

K. Pratt (Bethesda, United States)

14:25

Immune tolerance treatment in children and in adults with hemophilia and inhibitors

R. d'Oiron (Le Kremlin-Bicêtre, France)

14:50

Insights into the autoimmune response in acquired hemophilia A

A. Tiede (Hanover, Germany)

14:00

State of the Art, Room Sydney

VTE Intervention

Chairs:

V. Hach-Wunderle (Frankfurt am Main, Germany)

M. Schindewolf (Bern, Switzerland)

14:00

How to prevent chronic thromboembolic pulmonary hypertension after PE/VTE

S. Konstantinides (Mainz, Germany)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

14:25

Minimal-invasive endovascular treatment of acute deep vein thrombosis
N. Kucher (Bern, Switzerland)

14:50

Surgical and interventional therapy for chronic thromboembolic pulmonary hypertension (CTEPH)
C. B. Wiedenroth (Bad Nauheim, Germany)

15:30

Plenary Session II, Room San Francisco

Chairs:

P. A. Kyrle (Vienna, Austria)

E. Lindhoff-Last (Frankfurt am Main, Germany)

15:30

Fibrinogen, factor XIII, and red blood cells in thrombosis
A. S. Wolberg (Chapel Hill, United States)

16:00

Thrombophilia and pregnancy complications
S. Middeldorp (Amsterdam, The Netherlands)

16:45

Satellite Symposium LFB GmbH, Room Boston 1+2

Die aktuelle Herausforderung: atypische Von Willebrand-Patienten

Chairs:

J. Koscielny (Berlin, Germany)

W. Miesbach (Frankfurt am Main, Germany)

16:45

Begrüßung und Einführung
J. Koscielny (Berlin, Germany)

16:50

Individuelle Behandlung atypischer VWD-Patienten
C.-E. Dempfle (Mannheim-Lindenhof, Germany)

17:10

Diskussion



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

17:15

Von Willebrand-Faktor bei Patienten in der Herzchirurgie
U. Scholz (Leipzig, Germany)

17:35

Diskussion

17:40

Prevention of hemorrhage after implantation of mechanical circulatory support
S. Susen (Lille Cedex, France)

18:00

Diskussion

18:05

Zusammenfassung
J. Koscielny (Berlin, Germany)

16:45

Satellite Symposium LEO PHARMA GmbH, Room Delhi
Antikoagulation in Therapie und Prophylaxe - wohin geht die Reise?

Chairs:

H. Riess (Berlin, Germany)

16:45

VTE-Prophylaxe im klinischen Alltag - Hochrisikopatienten und perioperatives Management im Fokus
C. von Heymann (Berlin, Germany)

17:15

Update 2017: Was gibt es Neues in der Behandlung tumorassoziierter Thromboembolien?
H. Riess (Berlin, Germany)

17:45

German Evaluation of Cancer Associated Thrombosis (GECAT) - Eine prospektive Registerstudie zur Versorgung onkologischer Patienten mit VTE
R. Klamroth (Berlin, Germany)



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

16:45

Satellite Symposium Novo Nordisk Pharma GmbH, Room Kairo 1+2

Chancen einer individualisierten Hämophilietherapie - spezialisierte Physiotherapie - gewichtsadaptierte Dosierung - individuelle Pharmakokinetik

Chairs:

G. Auerswald (Bremen, Germany)

J. A. Kremer Hovinga (Bern, Switzerland)

16:45

Bedeutung der individualisierten Physiotherapie aus der Sicht des Hämostaseologen, Orthopäden und Physiotherapeuten. Ein Expertendialog

S. Halimeh (Duisburg, Germany)

17:25

GuardianTM9: Untersuchung der Pharmakokinetik von Turoctocog alfa im Verhältnis zum BMI

G. Goldmann (Bonn, Germany)

17:45

Individual pharmacokinetic assessment - the WAPPS-Hemo Project

A. McEneny-King (Waterloo, Canada)

16:45

Satellite Symposium Stago, Room Shanghai 1+2

Laborkontrolle der Antikoagulation

Chairs:

D. Tsakiris (Basel, Switzerland)

16:45

Monitoring der Heparine: APTT, Thrombinzeit oder Anti-FXa?

W. A. Wuillemin (Luzern, Switzerland)

17:05

Diskussion

17:15

Monitoring der DOAC: Wann, wie, bei wem?

D. Peetz (Berlin, Germany)

17:35

Diskussion



61ST ANNUAL MEETING SOCIETY OF THROMBOSIS AND HEMOSTASIS RESEARCH

17:45

Thrombophilie-Screening und Interferenzen durch die DOAC
S. Eichinger-Hasenauer (Vienna, Austria)

18:05

Diskussion, Zusammenfassung und Schlussbemerkungen

16:45

Satellite Symposium Shire - Baxalta Deutschland GmbH, Room Shanghai 3+4
One size does not fit all - Individualisierte Behandlungsziele unter
ADYNOVI-Prophylaxe
Chairs:

A. Huth-Kühne (Heidelberg, Germany)

16:45

Begrüssung und Einleitung
A. Huth-Kühne (Heidelberg, Germany)

16:55

Die Evolution der Hämophilie A Behandlung
F. Langer (Hamburg, Germany)

17:25

Der pädiatrische EHL-Patient – alles gleich oder doch ganz anders?
C. Bidlingmaier (Munich, Germany)

17:50

Wer EHL sagt, muss auch PK sagen
I. Hegemann (Zurich, Switzerland)